Litcius/Paper detail

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Amer M. Zeidan, Pierre Fenaux, Marco Gobbi, Jiřı́ Mayer, Gail J. Roboz, Jürgen Krauter, Tadeusz Robak, Hagop M. Kantarjian, Jan Novák, W Wiktor-Jędrzejczak, Xavier Thomas, Mario Ojeda‐Uribe, Yasushi Miyazaki, Yoo Hong Min, Su‐Peng Yeh, Joseph Brandwein, Liana Gercheva, Judit Demeter, Elizabeth A. Griffiths, Karen Yee, Jean‐Pierre J. Issa, Jan Philipp Bewersdorf, Harold Keer, Yong Hao, Mohammad Azab, Hartmut Döhner

2022Blood36 citationsDOIOpen Access PDF

Topics & Concepts

AzacitidineDecitabineMedicineChemotherapy regimenChemotherapyOncologyInternal medicineIntensive care medicineChemistryDNA methylationGeneGene expressionBiochemistryAcute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors ResearchHematopoietic Stem Cell Transplantation
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy | Litcius